Design and Rationale for comParison Between ticagreLor and clopidogrEl on mIcrocirculation in Patients with Acute cOronary Syndrome Undergoing Percutaneous Coronary Intervention (PLEIO) Trial

It has been previously demonstrated that ticagrelor can reduce mortality compared to clopidogrel in acute coronary syndrome (ACS) patients. However, the mechanism for this mortality reduction remains uncertain. The objective of the present study is to assess the impact of chronic ticagrelor treatment on microvascular circulation. A total of 120 participants aged 20–85 years with clinical diagnosis of ACS will be randomized in a 1:1 fashion to the following two groups: ticagrelor 90 mg twice daily; clopidogrel 75 mg once daily. To evaluate the status of microcirculation, the primary end point is coronary microvascular dysfunction measured using an index of microcirculatory resistance (IMR) at 6 months after receiving the study agent. The purpose of this trial is to investigate whether ticagrelor, beyond its antiplatelet efficacy, could improve coronary microcirculation more effectively than clopidogrel for patients with ACS.

• Publication year

  2018

• Venue

  Journal of Cardiovascular Translational Research

• Publication date

  2018-01-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s12265-017-9783-8PMID 29344840PMCID 5846973
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ticagrelor Versus Clopidogrel on Myocardial Infarct Size in Patients Undergoing Primary Percutaneous Coronary Intervention.

  2017cited by this paper
• Meta-Analysis of the Relative Efficacy and Safety of Oral P2Y12 Inhibitors in Patients With Acute Coronary Syndrome.

  2017cited by this paper
• Randomised trial to compare a protective effect of Clopidogrel Versus TIcagrelor on coronary Microvascular injury in ST-segment Elevation myocardial infarction (CV-TIME trial).

  2016cited by this paper
• Protective Effects of Ticagrelor on Myocardial Injury After Infarction

  2016cited by this paper
• 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infa

  2016cited by this paper
• 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards).

  2015cited by this paper
• 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards).

  2015cited by this paper
• No-Reflow Phenomenon

  2014cited by this paper
• Prognostic Role of Platelet Reactivity in Patients With Acute Coronary Syndromes

  2014cited by this paper
• Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome.

  2014cited by this paper
• Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).

  2013cited by this paper
• Cardiovascular adenosine receptors: expression, actions and interactions.

  2013cited by this paper
• Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans.

  2013cited by this paper
• Identification and Assessment of Adherence-Enhancing Interventions in Studies Assessing Medication Adherence Through Electronically Compiled Drug Dosing Histories: A Systematic Literature Review and Meta-Analysis

  2013cited by this paper
• Coronary microvascular dysfunction.

  2013cited by this paper
• ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.

  2012cited by this paper
• Purinergic signaling during inflammation.

  2012cited by this paper
• Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery.

  2012cited by this paper
• Prognostic Value of the Index of Microcirculatory Resistance Measured After Primary Percutaneous Coronary Intervention

  2012cited by this paper
• Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry

  2012cited by this paper
• Mechanisms of platelet activation in acute coronary syndromes.

  2012cited by this paper
• ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation

  2012cited by this paper
• Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium

  2011cited by this paper
• ACCF/AHA/SCAI Practice Guideline 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventi

  2011cited by this paper
• Mechanisms potentially contributing to the reduction in mortality associated with ticagrelor therapy.

  2011cited by this paper
• 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.

  2011cited by this paper
• 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).

  2011cited by this paper
• Mortality Benefit in PLATO Cannot Be Explained by Antiplatelet Properties of Ticagrelor

  2011cited by this paper
• International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors—An Update

  2011cited by this paper
• Adenosine release: a potential explanation for the benefits of ticagrelor in the PLATelet inhibition and clinical outcomes trial?

  2011cited by this paper
• The index of microcirculatory resistance measured acutely predicts the extent and severity of myocardial infarction in patients with ST-segment elevation myocardial infarction.

  2010cited by this paper
• Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia results from the National Heart, Lung and Blood Institute WISE (Women's Ischemia Syndrome Evaluation) study.

  2010cited by this paper
• Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of Ticagrelor versus Clopidogrel in patients with stable coronary artery disease. The ONSET/OFFSET study.

  2010cited by this paper
• Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease: The ONSET/OFFSET Study

  2009cited by this paper
• Introduction to adenosine receptors as therapeutic targets.

  2009cited by this paper
• Ticagrelor versus clopidogrel in patients with acute coronary syndromes.

  2009cited by this paper
• Adenosine receptors and reperfusion injury of the heart.

  2009cited by this paper
• Prasugrel versus clopidogrel in patients with acute coronary syndromes.

  2007cited by this paper
• Coronary Microvascular Dysfunction

  2007cited by this paper
• Relationship between microvascular resistance and perfusion in patients with reperfused acute myocardial infarction.

  2007cited by this paper
• Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.

  2006cited by this paper
• Invasive Assessment of the Coronary Microcirculation: Superior Reproducibility and Less Hemodynamic Dependence of Index of Microcirculatory Resistance Compared With Coronary Flow Reserve

  2006cited by this paper
• A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial.

  2006cited by this paper
• Mechanism of vasodilation to adenosine in coronary arterioles from patients with heart disease.

  2005cited by this paper
• A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II).

  2005cited by this paper
• Hypoxia Modulates Adenosine Receptors in Human Endothelial and Smooth Muscle Cells Toward an A2B Angiogenic Phenotype

  2004cited by this paper
• Antiplatelet therapy for ischemic heart disease.

  2004cited by this paper
• Left ventricular function and cardiovascular events following adjuvant therapy with adenosine in acute myocardial infarction treated with thrombolysis, results of the ATTenuation by Adenosine of Cardiac Complications (ATTACC) study.

  2003cited by this paper
• Left ventricular function and cardiovascular events following adjuvant therapy with adenosine in acute myocardial infarction treated with thrombolysis

  2003cited by this paper
• Novel Index for Invasively Assessing the Coronary Microcirculation

  2003cited by this paper
• Platelet glycoprotein IIb/IIIa receptor blockade and coronary resistance in unstable angina.

  2002cited by this paper
• No-reflow phenomenon.

  2002cited by this paper
• Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology.

  1997cited by this paper
• Coronary microcirculation in health and disease. Summary of an NHLBI workshop.

  1997cited by this paper
• Intravenous adenosine suppresses cardiac release of endothelin after myocardial ischaemia and reperfusion.

  1993cited by this paper
• An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.

  1993cited by this paper
• Thrombolysis in myocardial Infarction (TIMI) trial–phase I

  1990influential reference
• Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase.

  1988cited by this paper

• Clinical efficacy and safety of tirofiban combined with conventional dual antiplatelet therapy in ACS patients undergoing PCI

  2021cites this paper
• Comparison of ticagrelor with clopidogrel on quality of life in patients with acute coronary syndrome

  2021cites this paper
• Comparison between ticagrelor and clopidogrel on myocardial blood flow in patients with acute coronary syndrome, using 13 N-ammonia positron emission tomography.

  2020cites this paper
• Comparative Non-Randomised Observational Study of Prasugrel and Ticagrelor in Patients Undergoing Percutaneous Coronary Intervention

  2020cites this paper
• Effects of Ticagrelor versus Clopidogrel in Patients with Coronary Bifurcation Lesions Undergoing Percutaneous Coronary Intervention

  2019cites this paper
• Comparison of the Effects of Ticagrelor and Clopidogrel on Microvascular Dysfunction in Patients With Acute Coronary Syndrome Using Invasive Physiologic Indices.

  2019cites this paper
• Ticagrelor and aspirin increased vein graft patency after coronary artery bypass grafting but does it matter?

  2018cites this paper